WO2017138788A1 - Composition anti-inflammatoire et anti-bactérienne contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang et un extrait naturel ou un produit de fermentation, et composition cosmétique destinée à prévenir ou à atténuer des dermopathies immunitaires contenant celle-ci - Google Patents

Composition anti-inflammatoire et anti-bactérienne contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang et un extrait naturel ou un produit de fermentation, et composition cosmétique destinée à prévenir ou à atténuer des dermopathies immunitaires contenant celle-ci Download PDF

Info

Publication number
WO2017138788A1
WO2017138788A1 PCT/KR2017/001510 KR2017001510W WO2017138788A1 WO 2017138788 A1 WO2017138788 A1 WO 2017138788A1 KR 2017001510 W KR2017001510 W KR 2017001510W WO 2017138788 A1 WO2017138788 A1 WO 2017138788A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
extract
composition
present
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/001510
Other languages
English (en)
Korean (ko)
Inventor
강상문
김한복
이기영
정혁광
신은진
차상주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A&pep Inc
Hoseo University Academic Cooperation Foundation
Original Assignee
A&pep Inc
Hoseo University Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A&pep Inc, Hoseo University Academic Cooperation Foundation filed Critical A&pep Inc
Publication of WO2017138788A1 publication Critical patent/WO2017138788A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an anti-inflammatory and antimicrobial composition containing the peptide and natural extracts or fermented products derived from the Cheonggukjang extract, more specifically, the cosmetic composition or food composition for anti-inflammatory and antimicrobial containing the composition as an active ingredient, immunogenic It relates to a cosmetic composition for preventing or improving skin diseases, and a pharmaceutical composition for preventing or treating inflammatory and infectious diseases.
  • Inflammation-related diseases include periodontitis, arthritis, gastritis, enteritis, rhinitis, sinusitis, sore throat, tonsillitis, and pneumonia.
  • Inflammation includes acute and chronic inflammation in preparation for the invasion of pathogens.
  • Inflammatory response is a kind of immune response that protects the human body, but excessive and long-term chronic inflammation is harmful to the human body, such as autoimmunity, allergies, and the like.
  • Chronic inflammation is also associated with cardiovascular disease, cancer, dementia and adult disease.
  • Inducible nitric oxide synthase (iNOS), NO (nitrogen monoxide), NO, transcription factors NF- ⁇ B, cytokines TNF- ⁇ , and IL-6 are factors that promote cell inflammation.
  • Drugs such as steroids and aspirin have been developed as an inflammatory agent, but these are known to have side effects such as immunosuppression, gastrointestinal diseases, bleeding, and hepatotoxicity. Accordingly, the development of new or improved therapeutics is essential and urgent.
  • the development of inflammatory drugs is underway in the field of inhibiting the secretion of inflammatory substances, preventing the adhesion of inflammatory cells, and researches actively searching for the active ingredient in natural products are actively conducted in connection with the problem of overcoming the above side effects.
  • Cheonggukjang is one of Korea's representative fermented foods made from soybean. It is one of the traditional types of soy sauce, soy sauce, soybean paste, and red pepper paste that have been commonly used to this day. The state has played an important role as a food. Cheonggukjang is made by using Bacillus subtilis called Bacillus subtilis attached to rice straw. It gives its unique taste and smell by enzymes produced by Bacillus subtilis during fermentation. In addition, it produces a large amount of viscous substance, which is a mixture of levan form fructan and polyglutamate derived from sugar and protein of raw soybeans. It is a high quality fermented soybean with high fat content.
  • isoflavones found in soybean have an anti-inflammatory effect of suppressing the expression of these factors.
  • Soybean fermented food Cheonggukjang is rich in isoflavones such as genistein and daidzein, amino acid polymers and peptides that are proteolytic products.
  • sebum is an oily secretion secreted from sebaceous gland to the surface of the hair and the surface of the epidermis, and its main chemical component is composed of cholesterol, fatty acids and ester compounds.
  • Sebum acts as a protective film to help protect the skin, but is mainly produced by the release of testosterone (testosterone), and can be overproduced by age, season, women's menstrual cycle, pregnancy, and stress.
  • testosterone testosterone
  • sebum which is a representative skin disease, is caused by excessive sebum secretion or the growth of acne bacteria.
  • Seborrheic dermatitis in particular, is a chronic inflammatory skin disease that occurs in the scalp and face where sebum secretion is active due to increased sebaceous glands, especially the eyebrows, nose, lips, ears, armpits, chest, and inguinal area. It is a skin disease.
  • the best way to treat and prevent seborrheic dermatitis is to control sebum secretion, control inflammatory reactions and eliminate acne.
  • the present inventors completed the present invention by confirming that the composition containing the cheonggukjang extract-derived peptide and natural extract or fermented product as an active ingredient has excellent anti-inflammatory and antibacterial activity.
  • the present invention is to solve the above problems, one object of the present invention is to provide an anti-inflammatory and antimicrobial composition comprising a peptide for inhibiting inflammatory cells derived from Cheonggukjang extract, and a plant extract or fermented product.
  • Still another object of the present invention is to provide an anti-inflammatory and antibacterial cosmetic composition containing the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Another object of the present invention to provide a cosmetic composition for the prevention or improvement of immune skin diseases containing the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Another object of the present invention to provide an anti-inflammatory and antimicrobial food composition containing the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Another object of the present invention to provide a pharmaceutical composition for preventing and treating inflammatory and infectious diseases containing the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Anti-inflammatory and antimicrobial composition for achieving the object as described above, Peptides for inhibiting inflammatory cells derived from Cheonggukjang extract; And at least one selected from the group consisting of Chelidonium majus Linne, Blackwood tree (Symplocos prunifolia), White matter (Thuja orientalis), Water lily (Nymphaea tetragona), Peach (phellodendron bark) and Peel (Peonia suffruticosa Andrew roots) Plant extracts or fermentations.
  • Peptides for inhibiting inflammatory cells derived from the extract of Cheonggukjang is for inhibiting inflammatory cells in which the sequence of Alanine (Ala) -phenylalanine (Phenylalanine, Phe) -Proline (Proline, Pro) -Glycine (Gly) is arranged in order.
  • the mixing ratio of the peptide and the plant extract is preferably 1: 100 to 100: 1 by weight.
  • Anti-inflammatory and antimicrobial cosmetic composition contains the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Cosmetic composition for the prevention or improvement of immune skin diseases contains the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Anti-inflammatory and antimicrobial food composition contains the anti-inflammatory and antimicrobial composition as an active ingredient.
  • a pharmaceutical composition for preventing and treating inflammatory and infectious diseases contains the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Cheonggukjang extract derived from the present invention and the composition containing the natural extract or fermented product as an active ingredient was confirmed that the anti-inflammatory and antibacterial effect is excellent.
  • composition of the present invention can be usefully used as an anti-inflammatory and antimicrobial composition, which can be used for cosmetics and foods.
  • composition of the present invention can be usefully used in the cosmetic composition for the prevention and improvement of immune skin diseases, can also be used in pharmaceutical compositions for the prevention and treatment of inflammatory and infectious diseases.
  • Figure 1 is a photograph of the concentrate after extraction with 70% ethanol and the raw material of two plants (top; bark, bottom; yellowish white) according to an embodiment of the present invention.
  • Figure 3 is a photograph of the antimicrobial activity against the acne (Propionibacterium Acnes) according to a preferred embodiment of the present invention.
  • Figure 4 is a photograph of the antimicrobial activity of the acne bacteria (Propionibacterium Acnes) of the Cheonggukjang peptide.
  • the present invention provides a peptide for inhibiting inflammatory cells derived from the extract of Cheonggukjang; And at least one selected from the group consisting of Chelidonium majus Linne, Blackwood tree (Symplocos prunifolia), White matter (Thuja orientalis), Water lily (Nymphaea tetragona), Peach (phellodendron bark) and Peel (Peonia suffruticosa Andrew roots) It provides an anti-inflammatory and antimicrobial composition comprising a natural extract or fermentation.
  • Peptides for inhibiting inflammatory cells derived from the extract of Cheonggukjang is for inhibiting inflammatory cells in which the sequence of Alanine (Ala) -phenylalanine (Phenylalanine, Phe) -Proline (Proline, Pro) -Glycine (Gly) is arranged in order.
  • the mixing ratio of the peptide and the plant extract and the fermentation product is preferably 1: 100 to 100: 1 by weight.
  • Cheonggukjang extract according to the present invention can be obtained as follows.
  • the soybeans are washed, immersed in water, and then boiled using a pressurized steamer.
  • the soybeans are inoculated with Bacillus licheniformis, preferably Bacillus licheniformis B1, and fermented at 30-50 ° C. for 2-4 days, preferably 40-3 days; Lyophilizing the fermented fermented product to powder it; Dissolving the powdered powder in water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water, ethanol, butanol or a mixed solvent thereof, more preferably ethanol; Distilling the powder dissolved in the ethanol under reduced pressure; And lyophilizing the vacuum distilled powder.
  • the soybean includes foreign soybeans such as Korean, Chinese, and Japanese.
  • Bacillus subtilis (Bacillus subtilis) bacteria are used in the preparation of Cheonggukjang using soybeans, but the present invention specifically Bacillus licheniformis, more preferably Bacillus rickeniformis B1 bacteria. It is characterized by using.
  • extraction methods such as hot water extraction, cold sediment extraction, reflux cooling extraction, or ultrasonic extraction may be used.
  • a solvent water, ethanol, butanol or a mixed solvent thereof.
  • ethanol more preferably 80% ethanol, it was possible to obtain an extract effective for inflammation.
  • the inventors separated the peptide by performing HPLC from the Cheonggukjang extract as described in Example 2 below.
  • the peptide may be isolated from the extract of Cheonggukjang as described above, and may also be easily prepared by known peptide synthesis methods.
  • the peptide may be a peptide for inhibiting inflammatory cells.
  • the inflammatory cell may be a macrophage (macrophage) activated by lipopolysaccharide (LPS).
  • the present invention is an expression of at least one selected from the group consisting of inducible nitric oxide synthase (iNOS), nitric oxide (NO), transcription factors NF- ⁇ B, cytokine TNF- ⁇ , and IL-6 Or it may be a peptide for inhibiting inflammatory cells, characterized in that to reduce the activity.
  • the present inventors treated LPS (lipopolysaccharide), which causes inflammation, to Raw264.7 cells, which are immune cells, to increase the concentration of intracellular nitric oxide (NO), and then peptides and extracts.
  • the concentration of NO reduced by inhibiting the inflammatory response was measured using a Griess reagent.
  • FIG. 2 it was confirmed that the peptide of the present invention has excellent anti-inflammatory activity (see FIG. 2).
  • LPS Lipopolysaccharide
  • the present invention can be used for the treatment, amelioration and / or prevention of inflammatory diseases including the proliferation or metastasis of inflammation related cells or markers.
  • inflammation disease is a general term for a disease that has inflammation as a main lesion, but is not limited thereto, and preferably, atopy, psoriasis, dermatitis, allergy, arthritis, rhinitis, otitis media, sore throat, tonsillitis and cystitis , Nephritis, pelvic inflammatory disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematodes (SLE), atherosclerosis, asthma, arteriosclerosis, edema, rheumatoid arthritis, delayed allergy (type IV allergy), Graft rejection, graft-versus-host disease, autoimmune encephalomyelitis, multiple sclerosis, inflammatory bowel disease, arthritis, cystic fibrosis, diabetic retinopathy, rhinitis, ischemic-reperfusion injury, vascular restenosis, glomerulonephritis or gastrointestinal
  • the natural extract or fermented product may be a plant-derived extract or fermented product.
  • the plant extract or fermented product consists of Chelidonium majus Linne, Black ash tree (Symplocos prunifolia), White liquor (Thuja orientalis), Water lily (Nymphaea tetragona), Peach (phellodendron bark) and Peel (Paeonia suffruticosa Andrew roots) It is preferable to select at least 1 type from the group.
  • a polar solvent or a nonpolar solvent may be used.
  • Suitable as polar solvents include water, alcohols, preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol
  • Suitable as nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- Pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane,
  • the extraction of the plant is preferably hot water extraction and ultrasonic extraction using water and ethanol, wherein the concentration of ethanol is suitable 30 ⁇ 90%.
  • the ratio of plant and solvent is preferably 10: 100 to 10: 800 by weight, and the extraction time is suitably between 1 hour and 48 hours.
  • the plant extract of the present invention may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
  • the plant fermentation may be carried out by inoculating the plant with a microorganism capable of fermenting the plant, wherein the microorganism used may be used without limitation as long as it can ferment the plant.
  • Bacillus bacteria used in general plant fermentation may be used, and in general, Bacillus subtilis bacteria are used, but the present invention is particularly Lactobacillus acidophilus, more preferably Lactobacillus Lactobacillus acidophilus S1-76 can be used.
  • antibacterial is specifically preferably having antimicrobial activity against skin disease related bacteria, in particular acne (Propionibacterium Acnes), but is not limited thereto.
  • the antibacterial activity against acne bacteria was tested (see Experimental Example 1 below).
  • a mixture of 70% ethanol extract of Paeonia suffruticosa Andrew roots, Nymphaea tetragona, phellodendron bark, and fermented product it was positive control against the acne causative propionibacterium acne. Excellent antimicrobial activity was confirmed.
  • the present invention provides an anti-inflammatory and antimicrobial cosmetic composition containing the anti-inflammatory and antimicrobial composition as an active ingredient.
  • the cosmetic composition of the present invention includes components commonly used in cosmetic compositions in addition to the anti-inflammatory and antimicrobial compositions, and includes conventional auxiliaries such as sulfates, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers. .
  • the peptide and the plant extract of the present invention may be added in an amount of 0.1 to 50% by weight, preferably 1 to 10% by weight to the cosmetic composition usually contained.
  • Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art and include, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion (skin), nutrition lotion (milk lotion), nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder .
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanta, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • animal oil, vegetable oil, wax, paraffin, starch, tragacanta, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • tragacanta cellulose derivative
  • polyethylene glycol silicone
  • bentonite silica
  • talc talc
  • zinc oxide zinc oxide
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of spray, additionally chloro fluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystals
  • Soluble cellulose, aluminum metahydroxy, bentonite, agar or tragacanta and the like can be used.
  • the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the present invention provides a cosmetic composition for the prevention or improvement of immune skin diseases comprising the anti-inflammatory and antimicrobial composition as an active ingredient.
  • prevention refers to any action that inhibits or delays the development of an inflammatory disease by administration of the composition
  • treatment refers to any action that improves or benefits the symptoms of the inflammatory disease by administration of the composition. it means.
  • immune skin disease refers to a skin disease related to immunity, and specifically, atopy, seborrheic dermatitis, psoriasis, and the like, but are not limited thereto.
  • the present invention provides an anti-inflammatory and antimicrobial food composition comprising the anti-inflammatory and antimicrobial composition as an active ingredient.
  • Food composition according to the present invention can be prepared in the form of a mixture by mixing with known active ingredients known to be effective in the prevention and treatment of inflammatory diseases, functional food (nutritional supplement), health food ( It includes all forms, such as health food and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
  • a mineral-containing compound such as vitamin B, C, E or beta-carotene, Ca, Mg, Zn or phospholipids such as lecithin or maltose, oligosaccharide, amino acid as auxiliary ingredients together with the peptide and plant extract or fermented product.
  • Compounds such as these may be used. Among them, the use of a mixture of two or three components among vitamins C, E, beta carotene, maltol, and the like is more preferable because it can enhance the biological activity effect.
  • natural flavors such as plum, lemon, pineapple or herb, or natural fruit juice, chlorophyllin (Chlorophyllin)
  • Natural flavors such as plum, lemon, pineapple or herb, or natural juices, natural pigments and sweeteners such as chlorophyllin and flavonoids, such as fructose, honey, sugar alcohol, sugar and citric acid and sodium citrate Acidic agents can be mixed and used.
  • a preferred content of the peptide, the plant extract and the fermented product in the food composition of the present invention may include about 0.01 to 10% by weight based on the total weight of the food.
  • the present invention provides a functional food in the form selected from the group consisting of tablets, granules, and liquids comprising the food composition.
  • Functional food refers to foods that are designed and processed to fully exhibit biological control functions such as biological defense, biological rhythm control, and disease prevention and recovery.
  • the functional food production is not particularly limited other than those included in the food composition of the present invention, it may further contain the necessary ingredients for each food as a conventional food acceptable food supplement.
  • Tablets are easy-to-take and accurate dosages of powdered or crystalline materials that are aggregated and pressed into rounded discs or cones.
  • Functional food tablets of the present invention may include, but are not limited to, excipients such as lactose, starch, white sugar, mannitol, sorbitol, inorganic salts, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, May contain binders such as sodium carboxymethylcellulose and / or polyvinylpyrrolidine, optionally disintegrating or boiling mixtures such as starch, agar, alginic acid or its sodium salt and / or absorbents, colorants, flavors, And sweeteners.
  • the formulations may be prepared by conventional mixing, granulating or coating methods.
  • Granules refer to a round, granulated formulation, which can always take a certain proportion and are easy to take for mixed formulations. If necessary, colorants, fragrances, etc. may be added to the granules of the present invention, and may be coated with a suitable coating agent.
  • a liquid formulation refers to a liquid formulation, and stabilizers, copulating agents, preservatives, etc. may be added as necessary for the present invention.
  • the functional beverage composition of the present invention may further include fruit extract for flavor improvement.
  • Fruit extracts have the advantage of being able to use various active ingredients with fruit with flavor improvement.
  • the fruit used in the fruit extract is not limited thereto, but may include at least one selected from pineapple, lemon, citrus, orange, apple, pear, grapefruit, apricot, strawberry, peach, melon, guava, lemon, and plum. Can be.
  • Other functional beverage compositions of the present invention may include known additives. As these known additives, nicotinic acid amide, vitamins A, B, C, D, E, folic acid, etc.
  • vitamins may be used as vitamins, and L-glycine, L-lysine, DL-methionine, and L- as amino acids.
  • Valine biotin, L-cysteine, L-cystine, L-tryptophan, L-threonine, L-phenylalanine, etc.
  • sweeteners are white sugar, glucose, fructose, fructooligosaccharides, isomaltoligosaccharides, malto oligosaccharides, Chitosan oligosaccharide, chito oligosaccharide, soy oligosaccharide, xylo oligosaccharide, isosaccharide (high fructose), invert sugar, aspartame, stevioside, sorbitol, mannitol, etc.
  • citric acid, DL-apple acid, succinic acid, etc. can be, as a stabilizer Among the sorbates, polysorbate 20, polysorbate 40, polysorbate 80 and the like may be used, and as preservatives, benzoic acid and its derivatives, dehydroacetic acid and its salts, sorbic acid and its salts and the like may be used. .
  • the present invention provides a pharmaceutical composition for the prevention and treatment of inflammatory and infectious diseases comprising the anti-inflammatory and antimicrobial composition as an active ingredient.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier, excipient or diluent.
  • pharmaceutically acceptable means a drug that does not cause a side effect and a sufficient amount to produce a therapeutic effect, the type of disease, the age, weight, health, sex, sensitivity of the patient to the drug It can be easily determined by those skilled in the art according to well-known factors in the medical field, such as the route of administration, the method of administration, the frequency of administration, the duration of treatment, the combination or the drug used simultaneously.
  • Carriers usable in the present invention include macromolecules that are slowly metabolized, such as liposomes, polysaccharides, polylactic acid, polyglycolic acid, polymeric amino acids, and amino acid copolymers.
  • Salts of inorganic acids such as, for example, hydrochloride, hydrobromide, phosphate and sulfate;
  • Pharmaceutically acceptable salts such as salts of organic acids such as acetates, propionates, malonates and benzoates; Liquids such as water, saline, glycerol and ethanol, and auxiliary substances such as wetting agents, emulsifiers or pH buffering materials can be used.
  • Pharmaceutically acceptable carriers are described in Remingtion's Pharmaceutical Sciences, Mack Publishing Company, 1991.
  • compositions comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
  • Solid preparations for oral administration may include tablet pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose or lactose ( lactose), gelatin and the like can be mixed.
  • lubricants such as magnesium stearate, talc and the like can also be used.
  • Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories It can have any one formulation selected from.
  • composition may be formulated in a unit dosage form suitable for intrabody administration of a patient according to a conventional method in the pharmaceutical field, preferably in the form of a formulation useful for the administration of a peptide medicine, and is commonly used in the art.
  • Oral or intradermal, intravenous, intramedullary, intramedullary, intraventricular, lung, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal tract, topical, sublingual, intravaginal or rectal Administration may be by parenteral administration routes including, but not limited to, routes.
  • the total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol that is administered in multiple doses for long periods of time.
  • the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease.
  • the pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
  • Boiled soybeans were inoculated with Bacillus licheniformis B1 bacteria, fermented at 40 ° C. for 3 days, and vacuum-dried to powder. Then, the powder was dissolved in 80% ethanol, distilled under reduced pressure, and vacuum-freeze-dried again to obtain the Chunggukjang extract.
  • LPS lipopolysaccharide
  • the plant extract extracted with 70% ethanol of Example 3 was diluted to 1mg / ml, 0.5mg / ml, 0.25mg / ml to test the antimicrobial activity against acne bacteria by concentration.
  • phenoxy ethanol was used as a positive control in order to compare and contrast the antimicrobial activity of the extracts. The results are shown in Table 1 and FIG. 3.
  • the paper disk test method was carried out by diluting the concentration of one species (alanine-phenylalanine-proline-glycine) in the Cheonggukjang peptide. And the experiment of the mixture containing 1 mg / ml of plant extracts and fermented products and one type of (Cheonggukjang peptides (alanine-phenylalanine-proline-glycine)) was carried out in the same manner.
  • Figure 3 is a photograph of the antimicrobial activity of the plant extract and fermented product of the present invention, Propionibacterium acne, a cause of acne of the plant extract and fermented product and peptide mixture, the plant extract and fermentation concentration It can be seen that the antibacterial effect is implemented in proportion.
  • MIC minimum inhibitory concentration
  • Extracts and fermentation of Chelidonium majus Linne, Black ash tree (Symplocos prunifolia), Thuja orientalis, Nymphaea tetragona, Phellodendron bark, Paekonia suffruticosa Andrew roots prepared in Example 1
  • the mixture of water and the peptide was added by disinfection filtration to a concentration suitable for RCM (reinforced clostridial broth), inoculated 1% of each of the activated acne strain culture in the experimental zone, and then put the sample in each concentration. After anaerobic culture for 72 hours under 37 ° C.
  • MIC minimal inhibitory concentration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition cosmétique anti-inflammatoire, anti-bactérienne, et de prévention ou d'atténuation d'une dermopathie immunitaire contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang (pâte de soja épaisse), et un extrait naturel ou un produit de fermentation. Plus particulièrement, la présente invention concerne une composition anti-inflammatoire et anti-bactérienne contenant : un peptide inhibiteur de cellules inflammatoires dérivé d'un extrait de chungkukjang ; et un extrait ou un produit de fermentation d'une ou plusieurs plantes choisies dans le groupe constitué par Chelidonium majus Linné, Symplocos prunifolia, Thuja orientalis, Nymphaea tetragona, des écorces de phellodendron et des racines de Paeonia suffruticosa Andrew. Il a été établi que la composition contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang, et un extrait naturel ou un produit de fermentation, de la présente invention, présente d'excellents effets anti-inflammatoires et anti-bactériens, et la composition de la présente invention peut être utile comme composition anti-inflammatoire et anti-bactérienne et peut être utile dans une composition cosmétique destinée à prévenir et à atténuer des dermopathies immunitaires.
PCT/KR2017/001510 2016-02-12 2017-02-10 Composition anti-inflammatoire et anti-bactérienne contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang et un extrait naturel ou un produit de fermentation, et composition cosmétique destinée à prévenir ou à atténuer des dermopathies immunitaires contenant celle-ci Ceased WO2017138788A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0016182 2016-02-12
KR1020160016182A KR101787600B1 (ko) 2016-02-12 2016-02-12 청국장 추출물 유래 펩타이드와 천연 추출물을 유효성분으로 함유하는 항염 및 항균 조성물 및 그를 포함하는 면역성 피부질환의 예방 또는 개선용 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2017138788A1 true WO2017138788A1 (fr) 2017-08-17

Family

ID=59563942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/001510 Ceased WO2017138788A1 (fr) 2016-02-12 2017-02-10 Composition anti-inflammatoire et anti-bactérienne contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang et un extrait naturel ou un produit de fermentation, et composition cosmétique destinée à prévenir ou à atténuer des dermopathies immunitaires contenant celle-ci

Country Status (2)

Country Link
KR (1) KR101787600B1 (fr)
WO (1) WO2017138788A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210078771A (ko) * 2019-12-19 2021-06-29 윤심 백굴채 및 감초의 유효성분을 포함하는 한약재 발효 조성물 및 그 제조방법

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220089816A (ko) 2020-12-21 2022-06-29 에이앤펩주식회사 항염 한방 발효 펩타이드를 포함하는 아토피 피부염 개선용 화장료 조성물 및 이의 제조 방법
KR102563718B1 (ko) * 2022-11-30 2023-08-08 에이앤펩주식회사 펩타이드 및 천연 발효물을 포함하는 피부염증 완화용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100742185B1 (ko) * 2006-02-20 2007-07-27 대한민국 항산화 활성을 가지는 펩타이드 함유 청국장 추출물 및이의 제조 방법
KR20120061725A (ko) * 2010-12-03 2012-06-13 신일제약주식회사 낙석등 및 목단피의 추출 혼합물을 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약제학적 조성물 및 상기 조성물의 제조방법
KR20140012964A (ko) * 2010-12-22 2014-02-04 라보라토이레즈 익스펜사이언스 폴리페놀이 풍부한 마카 지상부위 추출물 및 이를 포함한 조성물
KR101393978B1 (ko) * 2012-06-22 2014-05-12 호서대학교 산학협력단 청국장 추출물의 제조 방법, 이로부터 제조된 청국장 추출물이나 펩타이드를 유효성분으로 함유하는 염증 관련질환의 예방 및 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100742185B1 (ko) * 2006-02-20 2007-07-27 대한민국 항산화 활성을 가지는 펩타이드 함유 청국장 추출물 및이의 제조 방법
KR20120061725A (ko) * 2010-12-03 2012-06-13 신일제약주식회사 낙석등 및 목단피의 추출 혼합물을 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약제학적 조성물 및 상기 조성물의 제조방법
KR20140012964A (ko) * 2010-12-22 2014-02-04 라보라토이레즈 익스펜사이언스 폴리페놀이 풍부한 마카 지상부위 추출물 및 이를 포함한 조성물
KR101393978B1 (ko) * 2012-06-22 2014-05-12 호서대학교 산학협력단 청국장 추출물의 제조 방법, 이로부터 제조된 청국장 추출물이나 펩타이드를 유효성분으로 함유하는 염증 관련질환의 예방 및 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, WOO HYUNG ET AL.: "Specific Oligopeptides in Fermented Soybean Extract Inhibit NF-kappa-dependent iNOS and Cytokine induction by Toll-like Receptor Ligands", JOURNAL OF MEDICINAL FOOD, vol. 17, no. 11, 2014, pages 1239 - 1246, XP055408022 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210078771A (ko) * 2019-12-19 2021-06-29 윤심 백굴채 및 감초의 유효성분을 포함하는 한약재 발효 조성물 및 그 제조방법
KR102382778B1 (ko) 2019-12-19 2022-04-05 윤심 백굴채 및 감초의 유효성분을 포함하는 한약재 발효 조성물의 제조방법

Also Published As

Publication number Publication date
KR101787600B1 (ko) 2017-10-27
KR20170095433A (ko) 2017-08-23

Similar Documents

Publication Publication Date Title
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2018084528A1 (fr) Composition antioxydante et d'amélioration de la peau
KR20240023411A (ko) 보툴리눔 독소 유래 펩타이드 단편, 및 이를 포함하는 피부 주름 개선용 화장료 조성물
WO2024181725A1 (fr) Centella asiatica rouge fermenté avec monascus et son utilisation
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
KR101787600B1 (ko) 청국장 추출물 유래 펩타이드와 천연 추출물을 유효성분으로 함유하는 항염 및 항균 조성물 및 그를 포함하는 면역성 피부질환의 예방 또는 개선용 화장료 조성물
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2017023099A1 (fr) Composition pour augmenter les bactéries lactiques intestinales et méthode de production de bactéries lactiques l'utilisant
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2023101440A1 (fr) Composition anti-inflammatoire contenant un extrait de germe d'arachide-nanoparticule d'or en tant que principe actif
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2012033329A2 (fr) Composition contenant un extrait d'oenanthe javanica en tant qu'ingrédient actif pour la prévention ou le traitement de troubles de l'apprentissage ou de troubles de la mémoire, et procédé pour la préparer
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
WO2022164183A1 (fr) Composition pour favoriser la pousse des cheveux comprenant des vésicules extracellulaires dérivées de lactobacillus curvatus en tant que principe actif
WO2022270688A1 (fr) Formulation microbienne anti-inflammatoire et antibactérienne comprenant un microbe cultivé dans un milieu contenant un extrait de filipendula glaberrima nakai et lysat associé
WO2019013374A1 (fr) Procédé de préparation d'un lyophilisat d'extrait éthanolique de taheebo
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
WO2019164090A1 (fr) Composition contenant un extrait de symplocarpe fétide ou une fraction de celui-ci utilisé comme principe actif pour l'atténuation des rides
WO2025110266A1 (fr) Utilisation d'un extrait de stewartia pseudocamellia pour protéger la vue ou soulager, prévenir ou traiter les maladies rétiniennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17750480

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17750480

Country of ref document: EP

Kind code of ref document: A1